| Identification | Back Directory | [Name]
NBI-31772 hydrate | [CAS]
374620-70-9 | [Synonyms]
NBI-31772 hydrate
NBI-31772 - CAS 374620-70-9 - Calbiochem
1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid | [Molecular Formula]
C17H11NO7 | [MDL Number]
MFCD20274527 | [MOL File]
374620-70-9.mol | [Molecular Weight]
341.27 |
| Chemical Properties | Back Directory | [Boiling point ]
764.7±60.0 °C(Predicted) | [density ]
1.696±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 0.14 mg/ml | [form ]
Greenish-yellow solid | [pka]
6.68±0.20(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
NBI-31772 is an insulin-like growth factor-I binding protein (IGFBP) ligand. | [in vivo]
NBI-31772 (5-100 μg; siv; administered at the onset of ischemia) dose-dependently reduces total infarct volume and cortical infarct volume at the onset of ischemia in rats with middle cerebral artery occlusion (MCAO) model[2].
NBI-31772 (50 μg; i.v.; administered 0, 1, 2, or 3 hours after MCAO) reduces cortical infarct size and brain swelling in rats with intraluminal suture MCAO model[2].
NBI-31772 (0.4 μM/strip; i.p.; 4 h) induces germinal vesicle rupture in zebrafish[4]. | Animal Model: | MCAO model rats[2] | | Dosage: | 5, 50 and 100 μg | | Administration: | siv; Drug administration during ischemic episodes | | Result: | Had similar effects on total lesion volume at the 50 and 100 μg doses.
Affected striatal lesion volume at the 50 μg dose. |
| Animal Model: | Intraluminal suture MCAO model rats[2] | | Dosage: | 50 μg | | Administration: | i.v.; Administration 0, 1, 2, or 3 hours after MCAO | | Result: | The greatest lesion reduction was observed when the drug was administered immediately after MCAO. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|